单克隆抗体
抗体
表位
癌症研究
免疫疗法
癌症免疫疗法
外周血单个核细胞
免疫系统
噬菌体展示
生物
受体
免疫学
化学
双特异性抗体
单域抗体
主要组织相容性复合体
免疫检查点
分泌物
阻断抗体
细胞外
癌症
MHC I级
靶向治疗
医学
黑色素瘤
癌症疫苗
T细胞
分子生物学
作者
Mengfei Dong,Wenhua Li,Tailin Wang,Ming Li,Jingyi Zhang,Xianglei Liu
摘要
Lymphocyte activation gene-3 (LAG-3) is a pivotal immune checkpoint receptor that exerts a negative regulatory effect on T-cell function. Although LAG-3-blocking antibodies have shown promising clinical potential, the inherent limitations of conventional monoclonal antibodies necessitate the development of novel antibody formats with enhanced biological and pharmacological properties. In this study, a panel of single-domain antibodies (sdAbs) targeting human LAG-3 was generated via phage display technology. Among these candidates, 2H-G7 was identified as a high-affinity sdAb that binds to LAG-3 with an equilibrium dissociation constant (KD) in the nanomolar range. Notably, 2H-G7 potently blocks the interactions of LAG-3 with both of its key ligands, fibrinogen-like protein 1 (FGL1) and major histocompatibility complex class II (MHC-II). Its capacity to restore impaired T-cell function was validated by quantifying interleukin-2 (IL-2) secretion and CD69 expression in stimulated primary human peripheral blood mononuclear cells (PBMCs). Epitope mapping studies localized the binding site of 2H-G7 to the D1D2 extracellular domains of LAG-3, distinct from relatlimab, a clinically approved LAG-3-blocking antibody serving as the benchmark. In a xenogeneic mouse model of non-small-cell lung cancer (NSCLC), 2H-G7-Fc exhibited superior tumor growth inhibition efficacy compared with relatlimab. These findings demonstrate that 2H-G7 is a promising lead candidate for the development of next-generation LAG-3-targeted tumor immunotherapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI